Gilead Reports Third Quarter 2026 Earnings with Significant Growth in Product Sales
Gilead Sciences, headquartered in Foster City, California and listed on NASDAQ under the ticker symbol GILD, has recently announced its financial results for the third quarter of 2026. The earnings report reveals an impressive performance, particularly in the field of HIV treatment and oncology, reflecting the strength and sustainability of Gilead's business model.
Key Financial Highlights
In Q3 2026, Gilead's product sales, excluding Veklury, reached $8.2 billion, a remarkable 16% increase compared to the same period last year. The increased sales are primarily driven by the strong performance of HIV products and novel oncology treatments. Specific details are as follows:
- - Biktarvy (Bictegravir) sales increased by 10% compared to the previous year, generating $4.1 billion, which reflects growing demand and improved average selling prices.
- - Sales from HIV products totaled $6.2 billion, an 18% increase year-over-year, fueled by increased demand for preventive therapies and better inventory management.
- - Despite the overall increase in product sales, royalties and contract revenues declined, mainly due to the absence of intellectual property sales recorded in the previous year.
Earnings Per Share (EPS) Insights
Diluted EPS for this quarter stood at $1.94, down from $2.43 in Q3 2025. This decrease is attributed to several factors:
- - A shift from net gains to net losses related to securities compared to the previous year.
- - Increased operating expenses and a higher effective tax rate.
However, non-GAAP diluted EPS saw a slight increase to $2.55 from $2.47, demonstrating the company's resilience in maintaining profitability despite external pressures.
Cash Flow and Financial Management
As of September 30, 2026, Gilead reported cash and cash equivalents amounting to $6.4 billion, significantly lower than the $10.6 billion reported at the end of 2025. This drop is largely due to extensive cash outflows tied to acquisitions, debt repayments, dividends, and share buybacks. Notably, Gilead achieved $5 billion in operating cash flow during this quarter, reflecting a solid operational foundation.
Strategic Growth in HIV and Oncology
The company's focus on HIV prevention and treatment continues to yield positive results. Groundbreaking advancements have led to the development of new therapies such as:
- - Approval of Bixlenvo™, a single-tablet regimen for adults with stable viral suppression, which marks a crucial step in simplifying HIV treatment.
- - Ongoing expansion of access to lenacapavir, a promising preventive therapy targeting high-prevalence regions, highlights Gilead’s commitment to global health.
Oncology remains a key area of focus, with Gilead's
TRODELVY® (sacituzumab govitecan-hziy) recently receiving approval for treating patients with advanced triple-negative breast cancer, further amplifying its product offerings in this critical therapeutic area.
Looking Ahead
Gilead has updated its full-year guidance for 2026, reflecting its robust Q3 performance. The company anticipates total product revenues to range between $31 billion and $31.3 billion, a notable increase from the previous estimate. Gilead aims to continue leveraging its established therapeutic portfolio while also exploring new avenues of growth through strategic acquisitions and research initiatives.
Overall, Gilead’s Q3 2026 earnings report showcases substantial growth in product sales, especially within the HIV and oncology sectors. The company is well-positioned for future success, backed by strong financial performance and a solid pipeline of innovative therapies designed to meet the needs of patients worldwide.